Company profile
Actinium Pharmaceuticals, Inc.
AMEX: ATNM · Healthcare · Biotechnology
#1045 of 1,418 Healthcare companies by revenue57th-percentile growth
EA Score
28DFH 21DQ 26GM 41SS 53
v0.1 · 65/100 weight · provisional
↑ listing tenure, revenue growth (YoY) · ↓ operating margin, net margin
Methodology →Revenue TTM
$90.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$33.9M
Employees
27
as of 2026-08-20
Market cap
$35.5M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$90.0k$90.0k2025
Net income-$33.9M-$33.9M2025
Operating income-$36.2M-$36.2M2025
Total assets$51.8M$51.8M2025
Liabilities$43.9M$43.9M2025
Equity$7.8M$7.8M2025
Revenue trend
FY2011 – FY2025 · USD
FY11
FY11
FY21
FY22
FY23
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Other Revenue Member100%
By geography
Not disclosed.
The read
What is Actinium Pharmaceuticals, Inc.’s revenue?
Actinium Pharmaceuticals, Inc. booked $90.0k in FY2025 revenue, growing 11% year over year — about the middle of the pack among Healthcare companies we track, at a -37652.2% net margin.
Peers · Healthcare
Profusa, Inc. Common Stock9DTherapeutic Solutions International, Inc.——Allied Corp.——Citius Pharmaceuticals, Inc.42DAIM ImmunoTech Inc.36DZecotek Photonics Inc.——Neighbors
New York →Key facts
CEOSandesh C. Seth
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeAMEX: ATNM
Employees27
IPO date2012-12-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.